Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Novan, Inc. (NOVN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.14-0.12 (-2.28%)
At close: 1:00PM EST
5.14 0.00 (0.00%)
After hours: 02:47PM EST
Advertisement

Novan, Inc.

4020 Stirrup Creek Drive
Suite 110
Durham, CA 27703
United States
919 485 8080
http://www.novan.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees23

Key Executives

NameTitlePayExercisedYear Born
Ms. Paula Brown Stafford M.P.H.Pres, CEO & Chairwoman897.86kN/A1965
Mr. John M. Gay CPACFO & Corp. Sec.408.03kN/A1976
Mr. Andrew J. NovakVP of Accounting & Bus. Operations and Chief Accounting OfficerN/AN/AN/A
Dr. Carri Geer Ph.D.Sr. VP & CTON/AN/AN/A
Mr. Cole IkkalaDirector of Investor Relations, Communications & Bus. Devel.N/AN/AN/A
Mr. Stanley Hollenbach BS,J.D.Sr. VP of R&DN/AN/AN/A
Mr. Brian M. JohnsonChief Commercial OfficerN/AN/A1966
Dr. Tomoko Maeda-Chubachi M.B.A., M.D., Ph.D.Chief Medical OfficerN/AN/AN/A
Ms. Elizabeth MessersmithSr. VP & Chief Devel. OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Novan, Inc., a clinical development-stage biotechnology company, provides nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is based in Durham, North Carolina.

Corporate Governance

Novan, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement